Custom cancer vaccine trial targets deadly brain tumors
NCT ID NCT05743595
Summary
This early-stage study is testing the safety and immune response of a personalized DNA vaccine combined with an immunotherapy drug (retifanlimab) for adults newly diagnosed with an aggressive type of brain cancer called unmethylated glioblastoma. The vaccine is custom-made for each patient based on their specific tumor. The main goal is to see if this combination is safe and can trigger a strong, targeted immune attack against the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNMETHYLATED GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.